AnzenBio

AnzenBio is a biotechnology company focused on developing "safety-first" gene and cell therapies through the implementation of advanced control systems. The company's core technology involves the integration of "safety switches" or "kill switches" into therapeutic vectors, allowing for the controlled elimination of engineered cells or the cessation of gene expression in the event of adverse reactions. By providing a mechanism to manage toxicity post-administration, AnzenBio aims to expand the therapeutic window and clinical utility of advanced genetic medicines. Based in Berkeley, California, the company leverages foundational research in viral vector engineering and synthetic biology to address critical safety hurdles in the field. Their approach is designed to make permanent genetic modifications safer and more accessible for a wider range of indications, including oncology and rare diseases. The company was co-founded by industry veterans and academic leaders from the University of California, Berkeley.